Home Newsfeeds Raymond James Maintains Outperform on Life Storage, Raises Price Target to $145

Raymond James Maintains Outperform on Life Storage, Raises Price Target to $145

Raymond James analyst Jonathan Hughes maintains Life Storage (NYSE:LSI) with a Outperform and raises the price target from $125 to $145.

byBenzinga Newsdesk

August 16, 2022

1 minute read

Raymond James analyst Jonathan Hughes maintains Life Storage (NYSE:LSI) with a Outperform and raises the price target from $125 to $145.

Baxter Plans Divesting Renal Care Business Into Separate Public Company, Shares Fall

By Vandana Singh

January 6, 2:33 PM

Baxter International Inc (NYSE:BAX) announced spinning off its Renal Care and Acute Therapies global business unit into an independent, publicly…

BAX

US Stock Futures Are Deep-Red: Analyst Sees Profit-Taking Bringing ‘Buying Opportunity’ As Traders Eye Fed’s Jackson Hole Event

By Shanthi Rexaline

August 22, 7:10 AM

Wall Street looks set to start the first trading session of the week on a markedly negative note, extending the downward momentum from Friday.

AMC

Momentus Says On Jan. 3, Announced Appointment Of Dennis Mahoney, As Interim CFO, Principal Accounting Officer Of Co., Effective As Of Jan. 7; Says Interim Chief Financial Officer, Mahoney Will Be Compensated At Rate Of $450/Hour

By Michael Horton

January 3, 6:25 PM

New Additions Join Experienced Leadership Team Focused on Growth

MNTS

EPKINLY Approved By U.S. FDA As The First And Only Bispecific Antibody To Treat Adult Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma

By Benzinga Newsdesk

May 19, 12:37 PM

AbbVie (NYSE:ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLYTM (epcoritamab-bysp), as the first and only T-cell engaging bispecific antibody for the treatment of adult patients

ABBV

Raymond James Maintains Outperform on Life Storage, Raises Price Target to $145

Related Posts

Baxter Plans Divesting Renal Care Business Into Separate Public Company, Shares Fall

US Stock Futures Are Deep-Red: Analyst Sees Profit-Taking Bringing ‘Buying Opportunity’ As Traders Eye Fed’s Jackson Hole Event

Momentus Says On Jan. 3, Announced Appointment Of Dennis Mahoney, As Interim CFO, Principal Accounting Officer Of Co., Effective As Of Jan. 7; Says Interim Chief Financial Officer, Mahoney Will Be Compensated At Rate Of $450/Hour

EPKINLY Approved By U.S. FDA As The First And Only Bispecific Antibody To Treat Adult Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma